Citigroup Inc Seres Therapeutics, Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 17,885 shares of MCRB stock, worth $12,877. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,885

Previous 88,329 79.75%

Holding current value

$12,877

Previous $123,000 89.43%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.75 - $1.56 $52,833 - $109,892	-70,444 Reduced 79.75%	17,885 $13,000
Q4 2023 Feb 09, 2024	SELL	$0.93 - $2.15 $368,738 - $852,459	-396,493 Reduced 81.78%	88,329 $123,000
Q3 2023 Nov 09, 2023	BUY	$2.33 - $5.07 $535,238 - $1.16 Million	229,716 Added 90.05%	484,822 $1.15 Million
Q2 2023 Aug 10, 2023	BUY	$4.67 - $6.55 $279,658 - $392,240	59,884 Added 30.67%	255,106 $1.22 Million
Q1 2023 May 11, 2023	BUY	$4.95 - $6.09 $260,127 - $320,035	52,551 Added 36.83%	195,222 $1.11 Million

Q4 2022 Feb 09, 2023	SELL	$5.09 - $9.05 $244,742 - $435,151	-48,083 Reduced 25.21%	142,671 $798,000
Q3 2022 Nov 10, 2022	BUY	$3.5 - $7.2 $634,868 - $1.31 Million	181,391 Added 1937.32%	190,754 $1.23 Million
Q2 2022 Aug 10, 2022	SELL	$2.7 - $7.62 $115,997 - $327,370	-42,962 Reduced 82.11%	9,363 $32,000
Q1 2022 May 12, 2022	SELL	$6.3 - $8.84 $1.35 Million - $1.89 Million	-214,130 Reduced 80.36%	52,325 $373,000
Q4 2021 Feb 10, 2022	SELL	$6.02 - $11.43 $339,895 - $645,349	-56,461 Reduced 17.48%	266,455 $2.22 Million
Q3 2021 Nov 10, 2021	BUY	$5.46 - $22.6 $1.76 Million - $7.3 Million	322,916 New	322,916 $2.25 Million

Others Institutions Holding MCRB

# of Institutions

100

Shares Held

62.7M

Call Options Held

36.9K

Put Options Held

476K

View Full List

About Seres Therapeutics, Inc.

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $89.3M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

More about MCRB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account